- Home
- APRE vs INAB Comparison
APRE vs INAB Comparison
Compare APRE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- INAB
- Stock Information
- Founded
- APRE 2006
- INAB 2016
- Country
- APRE United States
- INAB United States
- Employees
- APRE N/A
- INAB N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- INAB Health Care
- Exchange
- APRE Nasdaq
- INAB Nasdaq
- Market Cap
- APRE 21.3M
- INAB 24.0M
- IPO Year
- APRE 2019
- INAB 2021
- Fundamental
- Price
- APRE $2.92
- INAB $0.32
- Analyst Decision
- APRE Strong Buy
- INAB Strong Buy
- Analyst Count
- APRE 2
- INAB 3
- Target Price
- APRE $15.50
- INAB $7.75
- AVG Volume (30 Days)
- APRE 13.3K
- INAB 833.0K
- Earning Date
- APRE 11-07-2024
- INAB 11-12-2024
- Dividend Yield
- APRE N/A
- INAB N/A
- EPS Growth
- APRE N/A
- INAB N/A
- EPS
- APRE N/A
- INAB N/A
- Revenue
- APRE $1,310,839.00
- INAB N/A
- Revenue This Year
- APRE $116.72
- INAB N/A
- Revenue Next Year
- APRE N/A
- INAB N/A
- P/E Ratio
- APRE N/A
- INAB N/A
- Revenue Growth
- APRE 130.31
- INAB N/A
- 52 Week Low
- APRE $2.15
- INAB $0.22
- 52 Week High
- APRE $8.85
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- APRE 34.50
- INAB 50.03
- Support Level
- APRE $2.87
- INAB $0.31
- Resistance Level
- APRE $3.35
- INAB $0.37
- Average True Range (ATR)
- APRE 0.32
- INAB 0.05
- MACD
- APRE -0.12
- INAB -0.00
- Stochastic Oscillator
- APRE 4.50
- INAB 30.77
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.